Related Experiment Video
Updated: Sep 25, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Neoadjuvant Chemoradiotherapy Versus Perioperative Chemotherapy ± Immunotherapy in Resectable Esophageal
Aroub Alkaaki1, Nianye Zheng2, Nicolas Toumbacaris3
1Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Thoracic Surgery, Department of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Objective:
We sought to compare pathologic responses, perioperative outcomes, and early survival between induction chemoradiotherapy and perioperative chemotherapy ± immunotherapy in patients with resectable esophageal adenocarcinoma.
Methods:
Using our prospectively maintained institutional database, we retrospectively identified adult patients with resectable, locally advanced esophageal or gastroesophageal junction adenocarcinoma who underwent esophagectomy from January 2013 to October 2024 after induction chemoradiotherapy or perioperative chemotherapy ± immunotherapy. The primary outcome was rate of pathologic complete response. Secondary outcomes included rate of microscopically margin-negative resection, rate of pathologic node-negative status, and perioperative morbidity. Event-free survival and overall survival were estimated using Kaplan-Meier methods and were evaluated using Cox regression.
Results:
Of 811 patients, 650 (80%) received chemoradiotherapy, and 161 (20%) received chemotherapy ± immunotherapy. Median follow-up was 29.9 months. Chemoradiotherapy was associated with higher rates of pathologic complete response (23% vs. 14%) and pathologic node-negative status (61% vs. 46%; both P<0.001 after adjustment). The rate of microscopically margin-negative resection was 96% in both groups. Two-year event-free survival was higher in the chemotherapy ± immunotherapy group (66% vs. 53%; adjusted hazard ratio, 0.53; P=0.007). Two-year overall survival was not statistically different between groups. On multivariable analysis, perioperative chemotherapy ± immunotherapy and pathologic complete response were independently associated with longer event-free survival.
Conclusions:
Both induction strategies achieved excellent perioperative outcomes. Despite higher rates of pathologic complete response with chemoradiotherapy, perioperative chemotherapy ± immunotherapy was associated with longer early event-free survival. This association was attenuated in propensity score-matched and 90-day landmark analyses. Longer follow-up is warranted.
